Vanguard Capital Management
DMAC icon

Vanguard Capital Management’s DiaMedica Therapeutics DMAC Stock Holding History

Vanguard Capital Management’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.5M Buy
355,523
+22,067
+7% +$136K ﹤0.01% 3340
2026
Q1 		$2.26M Buy
+333,456
New +$2.64M ﹤0.01% 3321

Other funds holding DMAC

CLG
Cooperman Leon G $3.55B AUM 41.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Vanguard Capital Management's DMAC Position: Q2 2026 in Review

Vanguard Capital Management increased its DiaMedica Therapeutics (DMAC) stake by 6.6% in Q2 2026, buying an estimated $136K and bringing the position to 355,523 shares worth $2.5M. The position accounts for ﹤0.01% of the portfolio, ranked #3340.

Vanguard Capital Management first reported a position in DMAC in Q1 2026 and has held it in 2 quarters since. 89 funds tracked by Wall St. Rank hold DMAC as of Q2 2026.

  • Vanguard Capital Management held 355,523 shares of DiaMedica Therapeutics worth $2.5M as of Q2 2026.
  • Vanguard Capital Management bought 22,067 DiaMedica Therapeutics shares in Q2 2026, an estimated $136K.
  • DiaMedica Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3340 holding.
  • Vanguard Capital Management first reported a position in DiaMedica Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 89 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.